Lipocine Inc. (NASDAQ: LPCN) awards director 2,000 stock options
Rhea-AI Filing Summary
Lipocine director Michael Grissinger received a grant of 2,000 stock options on August 3, 2026, each for Lipocine common stock at an exercise price of $2.11 per share and expiring on August 3, 2036. The options are subject to vesting: one-third of the shares vest on the one-year anniversary of August 3, 2027, and the remaining two-thirds vest monthly on a prorata basis over the following two years. The transaction was not reported as made under a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Grissinger Michael
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 2,000 | $2.11 | $4K |
Holdings After Transaction:
Stock Option (Right to Buy) — 2,000 shares (Direct)
Footnotes (1)
- F1. Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of August 3, 2027, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years.
Key Figures
Options granted: 2,000 shares
Exercise price: $2.11 per share
Expiration date: 2036-08-03
+3 more
6 metrics
Options granted
2,000 shares
Stock options for Lipocine common stock granted to director Michael Grissinger
Exercise price
$2.11 per share
Exercise price for the 2,000 granted stock options
Expiration date
2036-08-03
Expiration of the reported stock option grant
Post-transaction derivative holdings
2,000 options
Total stock options held after this reported grant
Initial vesting tranche
1/3 of shares
Vests on the one-year anniversary of August 3, 2027
Remaining vesting period
2 years
Remaining two-thirds of the award vest monthly over the following two years
Key Terms
Stock Option (Right to Buy), vesting, Common Stock
3 terms
Stock Option (Right to Buy) financial
"Security title reported as Stock Option (Right to Buy) for common stock"
vesting financial
"Subject to vesting whereby 1/3 of the shares will vest on the one year anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Common Stock financial
"Underlying security title identified as Common Stock for the option award"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Lipocine (LPCN) director Michael Grissinger report on this Form 4?
Michael Grissinger reported receiving a grant of 2,000 stock options for Lipocine common stock. The options have a $2.11 per share exercise price, expire on August 3, 2036, and vest over three years beginning one year after August 3, 2027.
How many Lipocine (LPCN) stock options were granted and at what exercise price?
The filing reports a grant of 2,000 stock options to director Michael Grissinger. Each option is exercisable for Lipocine common stock at an exercise price of $2.11 per share, as specified in the transaction details.
What is the vesting schedule for Michael Grissinger's LPCN stock options?
The options are subject to vesting, with one-third of the shares vesting on the one-year anniversary of August 3, 2027. The remaining two-thirds of the award vest monthly on a prorata basis over the following two years.
When do the Lipocine (LPCN) options awarded to Grissinger expire?
The granted stock options expire on August 3, 2036. After that expiration date, any unexercised options from this 2,000-share award will no longer be exercisable for Lipocine common stock.
Were Michael Grissinger’s Lipocine (LPCN) option grants made under a Rule 10b5-1 plan?
The filing’s Rule 10b5-1 checkbox is not checked, indicating the transaction was not reported as made under a Rule 10b5-1 trading plan. The award appears as a standard director option grant.